Malignant Tumor Grading: Criteria, Systems, and Clinical Impact

Tumor grading assesses histologic differentiation and proliferative activity to predict biologic aggressiveness. Distinct from staging (extent of spread).

Core Grading Parameters

1. Differentiation: Well (Grade 1) → Moderate (Grade 2) → Poor/Undifferentiated (Grade 3/4).
2. Pleomorphism: Nuclear size/shape variation.
3. Mitotic count: Figures per high-power field (HPF).
4. Atypia: Nuclear hyperchromasia, irregular membranes, prominent nucleoli.
5. Necrosis / Infiltration pattern: Geographic necrosis, perineural/lymphovascular invasion.

Common Systems

• Nottingham (Elston-Ellis) – breast (tubules, nuclei, mitoses).
• Gleason / Grade Group – prostate (architectural pattern).
• WHO CNS grades – brain tumors (1–4).
• FNCLCC – sarcomas (differentiation, mitoses, necrosis).
• Fuhrman / ISUP – renal cell carcinoma.

Clinical Utility

Guides adjuvant therapy decisions, surveillance intensity, and prognosis. High grade → more aggressive treatment (chemo, radiation), closer follow-up. Always interpreted alongside stage, molecular markers, and patient factors.